CIAS
VRDN icon

Capital Investment Advisory Services’s Viridian Therapeutics VRDN Stock Holding History

Capital Investment Advisory Services’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-33
Closed -$1K – 1473
2019
Q2 		$1K Buy
+33
New +$1.32K ﹤0.01% 1367

Other funds holding VRDN

AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Investment Advisory Services's VRDN Position: Q3 2019 in Review

Capital Investment Advisory Services sold out of Viridian Therapeutics (VRDN) in Q3 2019, closing a stake of 33 shares — an estimated $1K sold.

Capital Investment Advisory Services first reported a position in VRDN in Q2 2019 and held it in 1 quarter. The position peaked at $1K in Q2 2019. 33 funds tracked by Wall St. Rank hold VRDN as of Q3 2019.

  • Capital Investment Advisory Services reported no remaining Viridian Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 33 Viridian Therapeutics shares in Q3 2019, an estimated $1K.
  • Capital Investment Advisory Services first reported a position in Viridian Therapeutics in Q2 2019 and held it in 1 quarter.
  • Capital Investment Advisory Services's Viridian Therapeutics position peaked at $1K in Q2 2019.
  • 33 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2019.

Based on Capital Investment Advisory Services's 13F filing for Q3 2019, filed 17 Oct 2019.